| Autor: |
Moghazy, Thanaa Fathi, Zaki, Moyassar Ahmad, Kandil, Noha Said, Maharem, Dalia Aly, Matrawy, Khaled Aly, Zaki, Moataz Ahmad, El-Banna, Alaa Mohamed Ismail |
| Předmět: |
|
| Zdroj: |
Alexandria Journal of Medicine; Dec2019, Vol. 55 Issue 1, p15-24, 10p |
| Abstrakt: |
Introduction: Vascular calcification (VC) is one of the factors involved in the increased cardiovascular risk observed in chronic kidney disease. Sclerostin is known to be a down regulator of bone mineralization, and a potential molecule linking the bone-vascular axis. The present study aimed at measuring serum sclerostin level in both dialyzed and undialyzed cases and correlating its serum level with both vascular and valvular types of calcification. Methods: This case control study was conducted on 82 Egyptian subjects of comparable age and gender divided into 20 apparently healthy volunteers as well as 62 chronic kidney disease cases of whom 31 cases were under maintenance hemodialysis (HD) for more than 6 months. Serum sclerostin was measured using an enzyme immunoassay. Results: Significantly higher median serum sclerostin values were observed in each of dialyzed and undialyzed cases compared to each others and to control group. Serum sclersotin was positively correlated with old age, male gender, and VC in dialyzed cases, and inversely correlated with estimated glomerular filtration rate in total number of cases. Diagnostic performance of serum sclerostin revealed a sensitive rather than a specific biomarker of both vascular and valvular types of calcification. Multiple regression analysis revealed an independent contribution of male gender, estimated glomerular filtration rate, and valvular calcification to serum sclerostin level. Conclusion: Serum sclerostin level could be used as a potential biomarker for both vascular and valvular types of calcification in chronic kidney disease cases regardless maintenance HD as a treatment modality. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
